BUCHANG PHARMA(SH:603858) Zheng Quan Zhi Xing·2025-08-07 10:14Core Viewpoint - The company plans to transfer a total of 5% equity in its subsidiary, Jinan Buchang Caigan Trading Co., Ltd., to various individuals and entities for a nominal price of 0 RMB, reducing its ownership from 93% to 90% [1][2][3] Transaction Overview - The company will transfer 2% equity to He Tao, 2% to Xie Jihui, and 1% to 1929 Health Technology (Guangzhou) Co., Ltd. [1][2] - The transaction does not constitute a related party transaction or a major asset restructuring as defined by regulations, and does not require shareholder approval [1][3] - There are no significant legal obstacles to the transaction [1][3] Parties Involved - The transferors include Fang Ke Rui, who is the General Manager of Shandong Buchang Qihang Pharmaceutical Sales Co., Ltd., and Zhou Yan Feng, who is the Regional Manager [3][4] - The transferee, 1929 Health Technology (Guangzhou) Co., Ltd., is a limited liability company with a registered capital of 1 million RMB and has been operating since November 2, 2022 [4][5] Financial Data of the Subsidiary - As of June 30, 2025, Buchang Caigan has not commenced actual business operations and thus has no financial data [5][6] - The company has a registered capital of 1 million RMB and is involved in various trading activities including medical supplies and health products [5][6] Impact on the Company - The equity transfer aligns with the company's strategic development and long-term interests, and is not expected to adversely affect its financial status or future operating results [7] - The company will continue to monitor market risks, management risks, and operational risks associated with the transaction [7]